Ambrosia Plasma relaunches - announces improvement in key ageing biomarkers
The Club interviews Jesse Karmazin, CEO, to find out more about the trial, the FDA warning, and the relaunch
Join the club for FREE to access the whole archive and other member benefits.
Young blood medicine maker for body rejuvenation.
Elevian develops regenerative medicines that target root-cause aging mechanisms. We are a spin out from Harvard, led by a team of serial entrepreneurs and Harvard scientists.
Elevian’s founders have identified blood factors that regulate aging and stimulate the body’s natural repair and regeneration mechanisms. One well published example, GDF11, reduces age-related cardiac hypertrophy, accelerates skeletal muscle repair, and improves cognitive function in aged mammals. We are developing biotherapeutics that regulate these blood factors.
Visit website: https://www.elevian.com/
Details last updated 12-Nov-2019
The Club interviews Jesse Karmazin, CEO, to find out more about the trial, the FDA warning, and the relaunch
Fight Aging! - 19-Oct-2022
Some really exciting developments with quite a few in clinical trials
Read more...FierceBiotech - 17-Sep-2021
$40 million for clinical research, lead program-stroke recovery focuses GDF11
Read more...FierceBiotech - 24-Nov-2020
rGDF11 in clinic targets multiple age related disease therapies
Read more...MIT Technology Review - 06-Sep-2018
Investigating ability of GDF11 to rejuvenate the body
Read more...Wired - 09-May-2018
GDF11 is a protein in the blood, which can stimulate cell growth and repair
Read more...